MedTrace Logo

Study of Ketamine as an Antidepressant in Major Depressive Disorder

NCT01573741 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-05-04

No results posted yet for this study

Summary

Primary Outcome Measures:

Evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment.

Secondary Outcome Measures:

Evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in psychiatric symptoms, and suicidal ideation.

Conditions

Interventions

DRUG

Ketamine

a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes

Sponsors & Collaborators

  • Shi Jinyun

    lead OTHER

Principal Investigators

  • Jianjun Yang, Dr · Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-12-31
Completion
2013-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573741 on ClinicalTrials.gov